Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Separately, TheStreet raised shares of Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Monday, October 16th.

Opiant Pharmaceuticals (NASDAQ:OPNT) opened at 36.59 on Friday. The firm’s 50 day moving average price is $35.94 and its 200-day moving average price is $17.87. Opiant Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $51.90. The stock has a market cap of $74.53 million, a P/E ratio of 12.45 and a beta of -0.97.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Friday, October 13th. The technology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.70. Opiant Pharmaceuticals had a net margin of 35.68% and a return on equity of 278.86%. The firm had revenue of $3.77 million during the quarter. Equities research analysts anticipate that Opiant Pharmaceuticals will post $0.50 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/29/valuengine-downgrades-opiant-pharmaceuticals-inc-opnt-to-buy.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Stock Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.